Skip to main content

NCBiotech News

  • John L. Atkins III, FAIA
  • Scientists studying the cancer-fighting potential of chemicals derived from broccoli and related plants may get a boost from an agreement recently signed by two North Carolina companies with a partner in England. Lalilab, of Durham, and PharmAgra Labs, of Brevard, have licensed a co-developed compound called Sulforadex to a 3-year-old British company, Evgen, for pharmaceutical development of their patented stabilized sulforaphane technology.
  • Research Triangle Park-based medical diagnostics company BioMedomics has added a new $745,000 federal grant to its war chest. BioMedomics, started in 2007 with the help of a $25,000 loan from the North Carolina Biotechnology Center, was awarded a two-year Small Business Innovation Research (SBIR) Phase II contract from the National Institutes of Health, to develop its portable system for detecting drug abuse.
  • Durham gastrointestinal drug development company Tranzyme Pharma has hired Gilead Sciences executive Franck Rousseau, M.D., to the newly created position of chief medical officer. More Durham medical device company Chesson Labs has raised $1.45 million of a $2 million goal in a second round of financing as it expands sales of Novaderm and Nuvavet, a liquid bandage product for human and veterinary use, respectively.
  • Current and future business people will have a chance to learn how patent law changes might affect them in the wake of recent patent reforms, during a Nov. 1 luncheon meeting at the Rock Bottom Restaurant in Charlotte. The Charlotte chapter of the Licensing Executives Society will feature a panel discussion by two area patent attorneys, moderated by Brad Fach, the chapter’s co-chair and assistant director of the University of North Carolina Charlotte’s Office of Technology Transfer. Panelists include:
  • Sequenom CFO Paul Maier, N.C. Gov. Bev Perdue announce 242-job, $19 M medical testing lab in RTP (Photo compliments of NCBIO)
  • Paul Ulanch Veteran business development specialist Paul Ulanch, Ph.D., M.B.A., has joined the North Carolina Biotechnology Center’s AgBiotech Group as Biotechnology Crops Development Director.
  •   An entrepreneurial Chapel Hill physician whose research commercialization has been helped by the North Carolina Biotechnology Center has won a prestigious national award.
  • It starts early in the morning but it’s worth the extra effort for the entrepreneurs, investors, students and faculty interested in North Carolina's growing bioscience community who gather for the annual BioSciences Forum.
  • Research Triangle Park agricultural biotechnology collaborators Bayer CropScience and Precision BioSciences have hit a scientific milestone just two years after Bayer bought into Precision’s DNA-tweaking technology.
  • Three people who have made major contributions to North Carolina’s leading life-science reputation are among those chosen to receive 2011 North Carolina Awards, the highest civilian honor the state bestows. Among the award winners to be honored at 8 p.m. on Thursday, Nov. 10, at the N. C. Museum of History are:
  • Charles Perou, Ph.D., professor of genetics, and pathology & laboratory medicine, and leader of the UNC Lineberger Comprehensive Cancer Center breast cancer research program at the University of North Carolina at Chapel Hill, has been appointed the May Goldman Shaw Distinguished Professor of Molecular Oncology Research. More
  • Technology transfer officials at three University of North Carolina System campuses are dividing nearly $250,000 in North Carolina Biotechnology Center grant funding to advance the commercial development of discoveries made at their universities. Technology Enhancement Grants will support the advancement of five inventions with significant market potential. The recipients include:
  • North Carolina’s leadership in the awe-inspiring evolution of regenerative medicine will be revisited Oct. 6 at North Carolina Biotechnology Center, where some of the world’s key creators of the fast-growing body-rebuilding field will gather to share ideas.
  • North Carolina has eight of the top-20 biotech and pharmaceutical employers that are highlighted in the current issue of Science, the magazine published by the American Association for the Advancement of Science. Of North Carolina’s 530 life-science companies, the Science ranking of the most-admired includes:
  •   Guest Post from Elizabeth Witherspoon, Ph.D., APR Courtesy of the North Carolina Translational and Clinical Sciences Institute (NC TraCS)
  • The North Carolina Biotechnology Center has awarded $60,500 in competitive research grants to a dozen undergraduate projects on eight campuses. The Undergraduate Research Fellowships match faculty mentors with science and engineering majors. Students across the state gain real-world research experience through these collaborative projects. For some awardees, these projects are first glimpses at biotechnology careers.
  • Two private companies with North Carolina facilities are among the 2011 Fierce 15 innovative firms chosen in the annual beauty pageant of life-science technologies sponsored by the online daily biotechnology blog, FierceBiotech. The companies are Intrexon, which has a division in Research Triangle Park, and Pearl Therapeutics, which has a facility in Raleigh.
  •   A distinguished feminist and bioethicist at UNC Charlotte has been tapped by the National Institutes of Health to serve a four-year term on a federal panel weighing big-picture issues involving science and ethics.


Subscribe to News & Events